Drop in PSA screening linked to elongate in metastatic prostate most cancers
(HealthDay)—Reductions in prostate-explicit antigen (PSA) screening are related with increases within the incidence of metastatic prostate most cancers at prognosis, according to a test presented on the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held just about from…